Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
Bristol-Myers Squibb's Lack of Update on Phase 3 Alzheimer's Trial 'Surprising,' Morgan Stanley Says
Published 1 week ago
Oct 31, 2025 at 2:37 PM
Positive
Auto